£26 million for spin-out developing advanced liver damage cell therapy
Resolution Therapeutics Ltd, a spin-out from the Centre for Regenerative Medicine (both Edinburgh, UK), has secured £26 million to further their research into a macrophage-based cell therapy targeting liver cirrhosis.
Resolution Therapeutics Ltd, a spin-out from the Centre for Regenerative Medicine (both Edinburgh, UK), has secured £26 million to further their research into a macrophage-based cell therapy targeting liver cirrhosis. More than 4,000 people die from liver cirrhosis in the UK each year and the only treatment, a liver transplant, is limited by the number of donor organs available. Resolution is investigating whether engineered macrophages could treat patients with compensated liver cirrhosis, where there is still some liver function remaining.
Professor Stuart Forbes, Scientific Co-founder, Resolution Therapeutics, and Director of the Centre for Regenerative Medicine, explained, “Our research indicates that a macrophage cell therapy may have a therapeutic effect in liver cirrhosis. By developing genetically modified macrophages we hope to increase the positive effects of these cells, and through this improve the lives of those suffering from chronic liver disease.”
“We are excited to partner with the world-class team in Edinburgh as together we build a business that will develop and commercialize macrophage cell therapies to treat severely ill patients who have no other treatment options. It is a very exciting opportunity, and we will be at the forefront of the development of a new kind of cell therapy,” commented Edward Hodgkin, Partner at Syncona and Chairman and CEO of Resolution.
https://www.regmednet.com/cell-therapy-weekly-26-million-for-spin-out-developing-advanced-liver-damage-cell-therapy/
ارسال به دوستان